BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2151448)

  • 21. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
    Kashimura M; Ohyashiki K
    Leuk Res; 2010 Aug; 34(8):e213-4. PubMed ID: 20299093
    [No Abstract]   [Full Text] [Related]  

  • 23. Leukemic synovitis as a presentation of myelomonocytic blast crisis of chronic myeloid leukemia.
    Al-Rayes HM; Al-Shaikh AA; Halim MA; Al-Qurashi FS; Al-Jurf MM
    Saudi Med J; 2001 Sep; 22(9):808-11. PubMed ID: 11590459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical manifestations of chronic granulocytic leukemia.
    Spiers AS
    Semin Oncol; 1995 Aug; 22(4):380-95. PubMed ID: 7638635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bestatin therapy of chronic myelogenous leukemia].
    Uzuka Y; Saito Y
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):207-14. PubMed ID: 8434958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
    Kuyama J; Take H
    Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis.
    Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M
    Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
    Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
    Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea.
    Jehn U; Heinemann V
    Cancer Detect Prev; 1998; 22(3):258-64. PubMed ID: 9618049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Splenomegaly and hepatomegaly at onset of blastic crisis in chronic myeloid leukaemia have prognostic importance.
    Parikh PM; Charak BS; Banavali SD; Koppikar SB; Giri NK; Kumar A; Saikia TK; Gopal R; Mazumdar AT; Advani SH
    J Assoc Physicians India; 1988 Nov; 36(11):653-5. PubMed ID: 3248993
    [No Abstract]   [Full Text] [Related]  

  • 32. Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
    Fang B; Song Y; Han Z; Wei X; Lin Q; Zhu X; Yang R; Sun J; Tian G; Liu X; Cao G; Shi Y; Nie N; Li D; Zhao RC
    Leuk Res; 2007 Oct; 31(10):1441-4. PubMed ID: 17383001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon induced cytogenetic improvement in CGL patients in haematological relapse post allograft.
    Aitchison R; Collins P; Newland AC
    Bone Marrow Transplant; 1990 Dec; 6(6):453. PubMed ID: 2097016
    [No Abstract]   [Full Text] [Related]  

  • 34. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia.
    Campiotti L; Grandi AM; Biotti MG; Ultori C; Solbiati F; Codari R; Venco A
    Am J Hematol; 2007 Mar; 82(3):231-3. PubMed ID: 17022045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
    Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disappearance of Ph1 chromosome with intensive chemotherapy and detection of minimal residual disease by polymerase chain reaction in a patient with blast crisis of chronic myelogenous leukemia.
    Honda H; Miyagawa K; Endo M; Takaku F; Yazaki Y; Hirai H
    Int J Hematol; 1993 Jun; 57(3):221-7. PubMed ID: 8364186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long duration priapism in blast crisis of chronic myeloid leukemia.
    Dogra PN; Kumar P; Goel R; Dash SC
    J Assoc Physicians India; 2004 Feb; 52():170. PubMed ID: 15656063
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival in chronic myeloid leukemia.
    Malhotra H
    J Assoc Physicians India; 1994 Apr; 42(4):345. PubMed ID: 7619118
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effectiveness of various chemotherapy regimens for patients with chronic myeloid leukemia in blast crisis].
    Abdulkadyrov KM; Bessmel'tzev SS; Rukavitzyn OA; Shilova ER; Shcherbakova EG
    Vopr Onkol; 1997; 43(3):284-9. PubMed ID: 9245083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.